Pentoxifylline in the treatment of autism
Phase 2
- Conditions
- Childhood autism.Childhood autism
- Registration Number
- IRCT138711161556N7
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion Criteria: DSM IV clinical diagnosis of autism, children and adolescents between the ages of 3 and 11 years (inclusive),
Exclusion Criteria
Presence of any active medical problem, any diagnosis in Axis I and II except for mental retatdation, history of allergy to Pentoxifylline, receiving any psychotropic medications during past two weeks prior to the trial, presence of aggressive behavior that needs Risperidone
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of Autism. Timepoint: Baseline and weerks 2, 4, 6, 8, 10. Method of measurement: Aberrant Behavior Checklist-Community (ABC-C) Rating Scale.
- Secondary Outcome Measures
Name Time Method